Pfizer has teamed up with BC Platforms to generate real-world evidence on cardiovascular diseases. The collaboration will leverage BC’s technology and Finnish health records to better understand atrial fibrillation patients.
Multiple organizations are involved in the initiative. The patient data will come from Turku University Hospital and other healthcare providers. BC is providing technology and research platforms, including access to data bank network BCRQUEST. And BC-partner Microsoft is handling the cloud infrastructure needed to index the information and make it available globally.
Pfizer is the beneficiary of these organizations’ efforts to make data accessible and analyzable. The Big Pharma is looking to the project to yield insights into complex cardiovascular diseases.
“We need data to fully understand and provide the best treatment outcomes for patients,” Jaakko Parkkinen, country medical director at Pfizer, said in a statement. “We believe that combining our expertise in treatment of cardiovascular diseases with BC Platforms' advanced genomic and clinical data management solutions through BCRQUEST.COM, we can gather and analyse important real world evidence to generate optimal patient outcomes.”
Landing Pfizer as a client caps off a big 12 months for BC. Since closing a $10 million series B in May, BC has rolled out its BCRQUEST platform and quickly landed three big-name clients: Amgen, Biogen and Pfizer. The drug developers are using the platform to generate real-world evidence in therapeutic areas of interest, including cardiovascular disease, oncology and multiple sclerosis.
BCRQUEST’s ability to generate such evidence is underpinned by access to genomic and clinical data held by biobanks around the world. BC has aggregated the resources—freeing drug developers from tackling potentially-tricky data harmonization tasks—and added an analytical layer to help companies make sense of the resource.